Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-03-21
2006-03-21
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S006120, C435S007100
Reexamination Certificate
active
07015016
ABSTRACT:
The invention concerns the use of a protein derived from cancel cells, cells infected by a virus or immune cells or an inactive fragment of said protein, said protein being initially an immunosuppressive and/or an angiogenic protein with local activity whereof said properties have been inactivated by at least 70% by a physical and/or chemical treatment, such as formolisation, carboxamidation, carboxymethylation, maleimidation or oxidation by oxygen bubbling, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed against said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, or the use of a DNA molecule corresponding to said protein inactivated by mutation or to said inactive fragment, for obtaining a medicine designed to provide a patient with mucosal immunity based on secretion of IgA secretory antibodies, pharmaceutical compositions for the mucous membranes and IgA antibodies.
REFERENCES:
patent: WO 96/27389 (1996-09-01), None
patent: WO 99/02712 X (1999-01-01), None
patent: WO 99/39735 (1999-08-01), None
patent: WO 00/03732 (2000-01-01), None
Murphy et al, Fields Virology, 2nd ED., 1990, Chapter 19, pp. 480-482.
Ginkel et al, The Journal of Immunology, 2000, p. 4778-4782.
Zhang et al (Journal of Virology, Oct. 2004, vol. 78, No. 19, 10249-10257.
Girard et al, “New Prospects for the Development of a Vaccine Against Human Immunodeficiency Virus Type 1,” Comptes Rendus de L'Academie des Sciences, Serie III. Sciences de la Vie, vol. 322, No11, Nov. 1999, pp. 959-966, France.
Boyaka et al. “Strategies for Mucosal Vaccine Development.” America Journal of Tropical Medicine and Hygiene, vol. 60. No. 4 Supplement, Apr. 1999, pp. 35-45.
Montgomery et al, “Induction of Secretory and Serum Anitbody Responses Following Oral Administration of Antigen with Bioadhesive Degradable Starch Microparticles,” Oral Microbiology and Immunology, vol. 13, No. 3, Jun. 1998, pp. 139-149.
Boyaka et al; “HIV Tat Protein Regulation of Mucosal Immunity,” Journal of Human Virology, vol. 3, No. 5, Sep. 2000, pp 10-15.
Browdy and Neimark PLLC
Neovacs
Salimi Ali R.
LandOfFree
Use of inactivated immunosuppressive or angiogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inactivated immunosuppressive or angiogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inactivated immunosuppressive or angiogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3593922